A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jul 2018
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Trastuzumab
- Indications Breast cancer; Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms KATHERINE
- Sponsors Roche
- 04 Jun 2018 Planned End Date changed from 22 Jul 2023 to 4 Apr 2023.
- 04 Jun 2018 Planned primary completion date changed from 22 Jul 2023 to 4 Apr 2023.
- 22 Jan 2018 Planned End Date changed from 31 Mar 2023 to 22 Jul 2023.